Effect of cathepsin K inhibitor basicity on in vivo off-target activities

Molecular Pharmacology

Volumn 73, Issue 1, 2008, Pages 147-156

  Desmarais, Sylvie ^a   Black, W Cameron ^a   Oballa, Renata ^a   Lamontagne, Sonia ^a   Riendeau, Denis ^a   Tawa, Paul ^a   Le, Thi Duong ^b   Pickarski, Maureen ^b   Percival, M David ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BALICATIB; CATHEPSIN B; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; L 006235; L 873724; N (CYANOMETHYL) N 2 [[2,2,2 TRIFLUORO 1 (4' METHYLSULFONYL)BIPHENYL 4 YL]ETHYL]LEUCINAMIDE; N [1 [[(CYANOMETHYL)AMINO]CARBONYL]CYCLOHEXYL] 4 [2 (4 METHYLPIPERAZIN 2 YL) 1,3 THIAZOL 4 YL]BENZAMIDE; UNCLASSIFIED DRUG;

ALKALINITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; RAT; SINGLE DRUG DOSE;

ANIMALS; CATHEPSINS; ENZYME INHIBITORS; MICE;

EID: 37349029510     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.107.039511     Document Type: Article

References (34)

1. Adami S, Supronik J, Hala T, Brown JP, Garnero P, Haemmerle S, Ortmann CE, Bouisset F, and Trechsel U (2006) Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res 21:S24.
2. Arai K, Kanaseki T, and Ohkuma S (1991) Isolation of highly purified lysosomes from rat liver: identification of electron carrier components on lysosomal membranes. J Biochem (Tokyo) 110:541-547.
3. Barrett AJ and Kirschke H (1981) Cathepsin B, cathepsin H, and cathepsin L. Methods Enzymol 80:535-561.
4. Black WC and Percival MD (2006) The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. Chembiochem 7:1525-1535.
5. Boyce BF, Xing L, Yao Z, Shakespeare WC, Wang Y, Metcalf CA, III, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, et al. (2006) Future anti-catabolic therapeutic targets in bone disease. Ann N Y Acad Sci 1068:447-457.
6. Close P, Neuprez A, and Reginster JY (2006) Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother 7:1603-1615.
7. Davis GA and Bloom FE (1973) Subcellular particles separated through a histochemical reaction. Anal Biochem 51:429-435.
8. Deaton DN and Tavares FX (2005) Design of cathepsin K inhibitors for osteoporosis. Curr Top Med Chem 5:1639-1675.
9. Falgueyret JP, Black WC, Cromlish W, Desmarais S, Lamontagne S, Mellon C, Riendeau D, Rodan S, Tawa P, Wesolowski G, et al. (2004) An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal Biochem 335:218-227.
10. Falgueyret JP, Desmarais S, Oballa R, Black WC, Cromlish W, Khougaz K, Lamontagne S, Masse F, Riendeau D, Toulmond S, et al. (2005) Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem 48:7535-7543.
11. Fonović M and Bogyo M (2007) Activity based probes for proteases: applications to biomarker discovery, molecular imaging and drug screening. Curr Pharm Des 13:253-261.
12. Gauthier JY, Black WC, Courchesne I, Cromlish W, Desmarais S, Houle R, Lamontagne S, Li CS, Masse F, McKay DJ, et al. (2007) The identification of potent, selective, and bioavailable cathepsin s inhibitors. Bioorg Med Chem Lett 17:4929-4933.
13. Gerard KW, Hipkiss AR, and Schneider DL (1988) Degradation of intracellular protein in muscle. Lysosomal response to modified proteins and chloroquine. J Biol Chem 263:18886-18890.
14. Gerbaux C, Van Bambeke F, Montenez JP, Piret J, Morlighem G, and Tulkens PM (1996) Hyperactivity of cathepsin B and other lysosomal enzymes in fibroblasts exposed to azithromycin, a dicationic macrolide antibiotic with exceptional tissue accumulation. FEBS Lett 394:307-310.
15. Grabowskal U, Chambers TJ, and Shiroo M (2005) Recent developments in cathepsin K inhibitor design. Curr Opin Drug Discov Devel 8:619-630.
16. Hara K, Kominami E, and Katunuma N (1988) Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages. FEBS Lett 231:229-231.
17. Kirschke H and Wiederanders B (1994) Cathepsin S and related lysosomal endopeptidases. Methods Enzymol 244:500-511.
18. Kleanthous C, Reilly M, Cooper A, Kelly S, Price NC, and Coggins JR (1991) Stabilization of the shikimate pathway enzyme dehydroquinase by covalently bound ligand. J Biol Chem 266:10893-10898.
19. Kominami E, Tsukahara T, Bando Y, and Katunuma N (1987) Autodegradation of lysosomal cysteine proteinases. Biochem Biophys Res Commun 144:749-756.
20. Lecaille F, Kaleta J, and Bromme D (2002) Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 102:4459-4488.
21. Li CS, Deschenes D, Desmarais S, Falgueyret JP, Gauthier JY, Kimmel DB, Leger S, Masse F, McGrath ME, McKay DJ, et al. (2006) Identification of a potent and selective non-basic cathepsin k inhibitor. Bioorg Med Chem Lett 16:1985-1989.
22. McGrath ME, Palmer JT, Bromme D, and Somoza JR (1998) Crystal structure of human cathepsin S. Protein Sci 7:1294-1302.
23. Montenez JP, Delaisse JM, Tulkens PM, and Kishore BK (1994) Increased activities of cathepsin b and other lysosomal hydrolases in fibroblasts and bone tissue cultured in the presence of cysteine proteinases inhibitors. Life Sci 55:1199-1208.
24. Pennypacker B, Rodan S, Black C, Oballa R, Masarachia P, Rodan G, and Kimmel DB (2006) Bone effects of cathepsin k inhibitors in the growing rabbit. J Bone Miner Res 21:S304.
25. Qian F, Chan SJ, Gong QM, Bajkowski AS, Steiner DF, and Frankfater A (1991) The expression of cathepsin B and other lysosomal proteinases in normal tissues and in tumors. Biomed Biochim Acta 50:531-540.
26. Rantakokko J, Aro HT, Savontaus M, and Vuorio E (1996) Mouse cathepsin K: CDNA cloning and predominant expression of the gene in osteoclasts, and in some hypertrophying chondrocytes during mouse development. FEBS Lett 393:307-313.
27. Robichaud J, Oballa R, Prasit P, Falgueyret JP, Percival MD, Wesolowski G, Rodan SB, Kimmel D, Johnson C, Bryant C, et al. (2003) A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J Med Chem 46:3709-3727.
28. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, and von Figura K (1998) Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci U S A 95:13453-13458.
29. Sellinger OZ, Beaubay H, Jacques P, Doyen A, and De Duve C (1960) Tissue fractionation studies. 15. Intracellular distribution and properties of beta-N-acetylglucosaminidase and beta-galactosidase in rat liver. Biochem J 74:450-456.
30. Shi GP, Webb AC, Foster KE, Knoll JH, Lemere CA, Munger JS, and Chapman HA (1994) Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 269:11530-11536.
31. Shirahama-Noda K, Yamamoto A, Sugihara K, Hashimoto N, Asano M, Nishimura M, and Hara-Nishimura I (2003) Biosynthetic processing of cathepsins and lysosomal degradation are abolished in asparaginyl endopeptidase-deficient mice. J Biol Chem 278:33194-33199.
32. Tawa P, Hell K, Giroux A, Grimm E, Han Y, Nicholson DW, and Xanthoudakis S (2004) Catalytic activity of caspase-3 is required for its degradation: stabilization of the active complex by synthetic inhibitors. Cell Death Differ 11:439-447.
33. Turk D, Turk B, and Turk V (2003) Papain-like lysosomal cysteine proteases and their inhibitors: drug discovery targets? Biochem Soc Symp 70:15-30.
34. Yasuda Y, Kaleta J, and Bromme D (2005) The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57: 973-993.